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Abstract 1 
Introduction 2 
Loss of renal function is associated with high mortality from cardiovascular disease (CVD). Patients 3 
with chronic kidney disease (CKD) have altered circulating adipokine and non-esterified fatty acid 4 
concentrations and insulin resistance, which are features of disturbed adipose tissue metabolism. 5 
Since dysfunctional adipose tissue contributes to the development of CVD, we hypothesize that 6 
adipose tissue dysfunctionality in patients with CKD could explain, at least in part, their high rates of 7 
CVD. Therefore we characterised adipose tissue from patients with CKD, in comparison to healthy 8 
controls, to search for signs of dysfunctionality.  9 
Methods 10 
Biopsies of subcutaneous adipose tissue from 16 CKD patients and 11 healthy controls were analysed 11 
for inflammation, fibrosis and adipocyte size. Protein composition was assessed using two-12 
dimensional gel proteomics combined with multivariate analysis. 13 
Results 14 
Adipose tissue of CKD patients contained significantly more CD68-positive cells, but collagen content 15 
did not differ. Adipocyte size was significantly smaller in CKD patients. Proteomic analysis of adipose 16 
tissue revealed significant differences in the expression of certain proteins between the groups. 17 
Proteins whose expression differed the most were alpha-1-microglobulin/bikunin precursor (AMBP, 18 
higher in CKD) and vimentin (lower in CKD). Vimentin is a lipid droplet-associated protein and 19 
changes in its expression may impair fatty acid storage/mobilisation in adipose tissue, while high 20 
levels of AMBP may reflect oxidative stress. 21 
Conclusion 22 
These findings demonstrate that adipose tissue of CKD patients shows signs of inflammation and 23 
disturbed functionality, thus potentially contributing to the unfavourable metabolic profile and increased 24 
risk of CVD in these patients.  25 
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Introduction 1 
Chronic kidney disease (CKD) is a global health problem with increasing prevalence and poor 2 
outcome,1 where cardiovascular disease (CVD) accounts for up to 50% of all-cause mortality.2 The 3 
reason for the high CVD risk is unclear, but cannot be explained simply by a decrease in filtering 4 
capacity of the kidneys. Indeed patients with a functioning kidney transplant still maintain higher CVD 5 
risk than the general population.3 Thus the cause of the metabolic dysregulation observed in CKD is 6 
complex, but a role for adipose tissue has been suggested. 7 
Adipose tissue buffers circulating non-esterified fatty acid (NEFA) concentrations, with a failure to do 8 
so leading to the development of an atherogenic dyslipidemia4 and lipotoxicity, which results in 9 
deterioration of tissue function and impaired lipid and glucose utilization.5,6 Adipocyte hypertrophy 10 
(increased cell size) is often followed by development of tissue fibrosis, hypoxia and secretion of pro-11 
inflammatory cytokines (such as TNF or IL-6) triggering inflammatory cell recruitment and deterioration 12 
of insulin signalling7 making adipose tissue dysfunctional. Malfunctioning adipose tissue contributes to 13 
the development of CVD locally and systemically. Local effects relate mainly to the direct impact on 14 
the vessel wall of fatty acids (FA) and adipokines released by perivascular adipose tissue, promoting 15 
expression of adhesion molecules, inflammatory cytokines and coagulation factors by endothelial 16 
cells8,9 and induce proliferation and migration of vascular smooth muscle cells (VSMC) and 17 
macrophage infiltration10,11 and inflamed visceral fat can directly promote atherosclerotic lesion 18 
development in the underlying vessel12. Systemic effects are attributed to both subcutaneous and 19 
visceral depots. Since the subcutaneous abdominal depot is the major determinant of circulating 20 
NEFA concentrations,13 its perturbed function promotes development of a pro-atherogenic lipoprotein 21 
profile. Furthermore, a shift towards secretion of a more pro-inflammatory adipokines by subcutaneous 22 
and/or visceral adipose tissue promotes VSMC migration, proliferation, osteogenic differentiation, 23 
induces a pro-thrombotic phenotype in vascular endothelial cells and upregulates mediators of 24 
vascular inflammation, like TNF, IL-2, IL-6 and CCL2.14,15 25 
Malfunctional adipose tissue is believed to promote CVD via the mechanisms described above. 26 
Although it is unknown whether these pathways are important contributors to the high rates of CVD in 27 
CKD patients, the hypothesis has been proposed.16-21 The supporting data include the observation that 28 
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CKD patients have elevated NEFA concentrations - an independent predictor of all-cause and 1 
cardiovascular death.21 Furthermore, CKD patients have perturbed circulating adipokine 2 
concentrations18,20 and increased systemic inflammation that correlates with fat mass.16 Indeed, 3 
visceral fat mass in peritoneal dialysis patients is an independent predictor of vessel dysfunction and 4 
therefore a risk factor for CVD.17 Unfavourable changes in markers reflecting oxidative stress, 5 
inflammation and impaired vessel function have been reported in subcutaneous adipose tissue of 6 
patients with kidney failure.22,23 Furthermore, a uremic milieu increases basal lipolysis rates and 7 
decreases expression of the lipid droplet-associated protein perilipin in primary adipocyte cultures,19 8 
which could lead to increased FA release. Finally, adipose lipoprotein lipase activity is decreased in 9 
CKD patients leading to the formation of lipoproteins with a pro-atherogenic lipid composition.24 Thus a 10 
range of studies have suggested that uremic adipose tissue may be dysfunctional, which could 11 
position adipose tissue as a contributing factor to the development of CVD in CKD patients. However a 12 
beneficial role of adipose tissue in CKD has also been suggested25 with high BMI being associated 13 
with better outcome in CKD patients,25,26 but this was true only when accompanied by normal or high 14 
muscle mass, indicating that any beneficial role of obesity is likely attributable to lean mass rather than 15 
adipose tissue. 16 
Many of the studies that indicate a role for adipose tissue in the development of CVD associated with 17 
CKD are based on systemic analyses, while direct analysis of adipose tissue, especially protein 18 
analysis, is largely lacking. Therefore we describe a proteomic approach to characterise the protein 19 
composition of subcutaneous adipose tissue in CKD patients, with the aim of better understanding if 20 
adipose tissue is dysfunctional and could contribute to the increased risk of CVD in patients with 21 
kidney failure.  22 
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Materials and Methods 1 
Subjects 2 
16 subjects with stage 5 CKD (recipients of kidney transplantation) and 11 healthy individuals (kidney 3 
donors) were enrolled in the study performed at Karolinska University Hospital (Huddinge). The 4 
number of subjects included in the different analyses varied and is indicated accordingly (Table 1). 5 
Inclusion criteria were: age 18-75 years and BMI 18-30 kg/m2. Exclusion criteria were: hypersensitivity 6 
for Xylocain, treated diabetes, and ongoing treatment with heavy immunosuppressives (such as 7 
cortisone). Of the 16 CKD patients prior to kidney transplantation, 7 had received haemodialysis (3.5-4 8 
hours, 3-4 times per week, urea reduction rate >80%), 3 received peritoneal dialysis, 2 received both 9 
types of dialysis and 4 had no previous dialysis treatment. The study was approved by the Stockholm 10 
Regional Ethics Committee and conducted according to the principles of the Declaration of Helsinki. 11 
All patients gave their written consent. 12 
Subcutaneous adipose tissue biopsies from the lower abdominal area were collected during kidney 13 
transplant surgery from both kidney recipients and donors. One part of the tissue was fixed and 14 
embedded in paraffin for histological analysis and one part was placed in AllProtect Reagent 15 
(Qiagen) and stored at -20°C for subsequent proteomic analysis. Fasting blood samples were 16 
collected one day before the operation and analysed using accredited methods in the clinical 17 
chemistry laboratory at Karolinska University Hospital. 18 
A separate group (n=9, 1 male and 8 females, age 48.3±7.5 years, 2 patients had diabetes and all had 19 
hypertension) of morbidly obese (BMI 41.2±4.4kg/m2) CKD patients (CKD stage 3-5) admitted to 20 
King’s College Hospital, London, UK for bariatric surgery was enrolled in the study. Subcutaneous 21 
adipose tissue biopsies from the abdominal region were collected during surgery and stored in 22 
AllProtect Reagent (Qiagen) at -20°C. These biopsies were used for proteomic analysis only. The 23 
study was approved by the British National Health Service Research Ethics Committee (NHS REC) 24 
and the use of biopsies in Sweden was approved by the Stockholm Regional Ethics Committee. All 25 
patients gave their written consent. 26 
Histological analyses 27 
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Five µm paraffin sections were used for histological analyses. For analysis of inflammation, a mouse 1 
CD68 (NCL-CD68-KP1, 1:200, Leica Biosystems Newcastle Ltd., Newcastle Upon Tyne, UK) antibody 2 
was used. Sections were counterstained with Harris hematoxylin (Histolab, Gothenburg, Sweden). 3 
Numbers of positive cells were counted in one entire section of each adipose tissue biopsy on two 4 
occasions by two independent observers who were blinded as to the sample status. These numbers 5 
were normalized for the total tissue area, measured using the ImageJ application (ImageJ 1.48 6 
[imagej.nih.gov/ij]). For evaluation of fibrosis, adipose tissue sections were stained with saturated 7 
picric acid containing 0.1% picrosirius red (Direct Red 80, Fluka), scanned (Hamamatsu NanoZoomer-8 
XR Digital slide scanner C12000) and visualized using Nano Zoomer Digital Pathology viewer 9 
software (U12388-01; NDP.view2 Viewing). Representative picrosirius red stainings of a control 10 
individual and a CKD patient are shown in Supplemental Figure 1. Collagen content was calculated 11 
as the percentage of the total section area. Adipocyte size was measured using the ImageJ 12 
application according to the method described previously.27 Representative images of ImageJ-13 
transformed pictures from a control individual and a CKD patient used for size quantification are 14 
shown in Supplemental Figure 2. 15 
Proteomics 16 
Protein extraction, two-dimensional electrophoresis, scanning, analysis and protein identification with 17 
tandem mass spectrometry (LC-MS/MS) were performed as described previously 28. Proteins were 18 
extracted from approximately 200mg of adipose tissue. For analytical gels, 5µg of CyDye-labelled total 19 
protein was loaded on each gel. The preparative gel was loaded with 1mg of internal standard (a 20 
mixture of adipose tissue protein extracts from all individuals pooled together) and stained with 21 
Pierce™ Silver Stain for Mass Spectrometry. Mass spectrometry analysis was performed by the 22 
Clinical Proteomics Mass Spectrometry facility, Karolinska Institutet/ Karolinska University Hospital/ 23 
Science for Life Laboratory. 24 
Western Blot 25 
Protein samples (20 µg) were separated by 10% sodium dodecyl sulfate polyacrylamide gel 26 
electrophoresis (SDS-PAGE) under reducing conditions and transferred to a polyvinylidene difluoride 27 
(PVDF) membrane (Bio-Rad). After incubation with 5% nonfat milk in a mixture of Tris-Buffered Saline 28 
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and Tween 20 the membrane was incubated with anti-vimentin (SC-66002, 1:500, Santa Cruz 1 
Biotechnology, Santa Cruz) or anti-AMBP (SC-81948, 1:400, Santa Cruz Biotechnology, Santa Cruz) 2 
antibody at 4 °C for 12 hours. Beta-actin was used as a loading control (1:250, Sigma Aldrich). 3 
Membranes were then incubated with horseradish peroxidase-conjugated anti-mouse or anti-rabbit 4 
antibodies (1:50000, Bio-Rad) and developed with ECL Prime (GE Healthcare, Little Chalfont, UK). 5 
Detection was performed with X-ray film Agfa CP-BU new (Agfa Healthcare, Mortsel, Belgium). 6 
Statistical analysis 7 
Comparisons between CKD patients and healthy controls were performed using a Student’s t-test for 8 
continuous variables or Pearson's Chi-squared test with Yates' continuity correction for gender 9 
distribution. Differences in CD68 positive cell count, collagen content and adipocyte cell size between 10 
groups were compared using a Mann Whitney U-test. Comparison of protein spot volumes between 11 
controls, lean CKD and obese CKD patients was performed using ANOVA and Fisher’s LSD post-hoc 12 
tests. ANCOVA was employed to test for differences in adipocyte size between patients and controls 13 
with BMI as a covariate. The analysis of the proteomic data (202 distinct protein spots) was performed 14 
by multivariate analysis (orthogonal projections to latent structures discriminant analysis, OPLS-DA) 15 
as described previously.28  16 
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Results 1 
 2 
We obtained subcutaneous abdominal adipose tissue from 16 patients with kidney failure (stage 5 3 
CKD) and 11 healthy individuals (kidney donors). The CKD patients had significantly lower BMI than 4 
the control group and several blood markers reflecting kidney failure and related complications differed 5 
significantly between the groups, but age, gender distribution and glucose concentrations were not 6 
different (Table 1). Concentrations of triglyceride, total cholesterol and high-density lipoprotein 7 
cholesterol in the CKD patients were within normal ranges (Table 1). 8 
 9 
Adipose tissue of CKD patients contains more CD68-positive cells and has smaller adipocytes than 10 
healthy controls 11 
Patients with CKD had significantly more CD68-positive cells in their subcutaneous adipose tissue 12 
than controls (Figure 1A, 1B and 1C). To assess whether adipose tissue in patients with CKD was 13 
fibrotic we stained for collagen using picrosirius red (Supplemental Figure 1), but quantification of this 14 
staining revealed no significant difference between the groups (Figure 1D). Mean adipocyte size 15 
(calculated from tissue sections, Supplemental Figure 2) was significantly smaller in patients with 16 
CKD compared to healthy individuals (Figure 1E). This difference in adipocyte size was maintained 17 
even after correction for BMI (p=0.017, data not shown). 18 
Proteomic analysis reveals differential protein composition in adipose tissue of healthy controls and 19 
patients with kidney failure 20 
To evaluate whether adipose tissue protein expression patterns differed between individuals with and 21 
without CKD, protein extracts from 13 lean CKD patients and 7 control individuals were analysed using 22 
two-dimensional gel electrophoresis and a total of 202 distinct protein spots were observed (Figure 2). 23 
Spot volumes (corresponding to protein expression levels) were measured and used to create a 24 
multivariate model (OPLS-DA), which revealed a clear separation of the CKD patients and healthy 25 
controls, indicating significant differences in the expression of certain proteins (Figure 3A). A graphical 26 
representation of the contribution of the 202 protein spots to the separation between the CKD and the 27 
controls is shown in the loading plot (Figure 3B). Quality parameters indicating a robust OPLS-DA 28 
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model were as follows: number of principal components = 1+1, Rx² (explained variance) = 0.245, Qy² 1 
(the cumulative fraction of the total variation of Y (presence of CKD) that can be predicted by the 2 
model) = 0.556, Ry² (explained variance for the Y component) = 0.902. Of the 202 spots, 47 3 
contributed significantly to the multivariate model and 18 of these were sufficiently large to be picked 4 
from the preparative gel for subsequent identification (Figure 2 and Figure 3C).  5 
Vimentin and alpha-1-microglobulin/bikunin precursor (AMBP) are the most differentially expressed 6 
proteins between CKD and healthy subjects 7 
The 18 adipose tissue protein spots that were significant in the OPLS-DA model and that could be 8 
picked from the preparative gel were identified by LC-MS/MS (Table 2). Four distinct spots differing 9 
slightly in their molecular weight (Figure 2) were identified to be vimentin (annotated vimentin_1-4, 10 
with vimentin_1 having the lowest and vimentin_4 the highest molecular weight). Further analysis was 11 
focused on the two proteins that contributed most strongly to the separation of the control and CKD 12 
groups and that were the most significant in the multivariate model, namely  vimentin_1 (expression 13 
lower in CKD) and alpha-1-microglobulin/bikunin precursor ( MBP, expression higher in CKD) (Figure 14 
3B and 3C). Of the other vimentin spots, vimentin_2 was also expressed at lower levels, while 15 
vimentin_3 and vimentin_4 were expressed at higher levels in CKD compared to controls. However, 16 
none of these vimentin spots contributed to the model as strongly as vimentin_1. To confirm 17 
differences in expression of vimentin and AMBP, adipose tissue protein extracts from controls and 18 
CKD patients were analysed by Western blot (Figure 4). In agreement with our 2D-gel results and 19 
data from others revealing multiple vimentin isoforms in human adipose tissue29 several vimentin 20 
isoforms were also identified by Western blot, as indicated by the multiple bands (Figure 4). In line 21 
with the 2D-gel results, the bands on the Western blots corresponding to the lowest molecular weight 22 
isoforms (similar to vimentin_1 and vimentin_2 on the 2D-gels) had lower expression in the CKD 23 
patients than in controls (visual assessment, Figure 4). Inspection of Western blots also clearly 24 
confirmed that adipose tissue from CKD patients contained more AMBP than healthy controls (Figure 25 
4). 26 
 27 
To confirm that the differential expression of vimentin_1 and AMBP proteins was truly related to CKD 28 
as opposed to a consequence of the difference in BMI between the groups (lower in CKD) we 29 
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performed an additional analysis using the same healthy controls and a group of 9 morbidly obese 1 
CKD subjects (BMI 41.2±4.4kg/m2), with greater BMI than the controls and whose adipose tissue had 2 
been analysed by proteomics in an identical fashion. In this new OPLS-DA model (which had model 3 
quality parameters reflecting a robust model: number of principal components = 1+1, Rx² = 0.42, Qy² = 4 
0.705, Ry² = 0.907) we found that vimentin_1 expression (spot volume) was significantly lower in 5 
obese patients with CKD and AMBP significantly higher in obese patients with CKD compared to 6 
healthy controls (Supplemental Figure 3). Direct comparison of the adipose tissue spot volumes of 7 
vimentin_1 and AMBP between healthy controls, lean CKD and obese CKD subjects showed 8 
vimentin_1 to be significantly lower (Figure 5A) and AMBP to be significantly higher (Figure 5B) in 9 
both CKD groups compared to the controls. These differences persisted even after correction for BMI, 10 
age and gender (control vs CKD lean: p=0.002 and p=0.0006 for vimentin_1 and AMBP respectively; 11 
control vs CKD obese: p=0.015 and p=0.004 for vimentin_1 and AMBP respectively; data not shown). 12 
Finally, we found no significant correlations between vimentin_1 or AMBP spot volumes and BMI when 13 
all 3 groups (lean CKD patients, slightly overweight controls and morbidly obese CKD patients) were 14 
combined (data not shown). These data suggest that the differential expression of vimentin_1 and 15 
AMBP proteins is indeed driven by the presence of kidney disease rather than by BMI. 16 
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Discussion 1 
 2 
We have characterised subcutaneous abdominal adipose tissue from lean patients with stage 5 CKD 3 
in comparison to healthy subjects and found increased numbers of phagocytic cells (CD68+) and 4 
smaller adipocytes in individuals with kidney failure, but no signs of fibrosis. Proteomic analysis 5 
revealed different adipose tissue protein profiles between the groups. Our data highlight decreased 6 
low molecular weight-vimentin isoforms and increased AMBP protein expression in adipose tissue as 7 
particularly important characteristics of uremic fat. To the best of our knowledge this is the first study to 8 
combine morphological and immunohistochemical characterisation with proteomic analysis of adipose 9 
tissue from patients with kidney disease. 10 
 11 
Systemic inflammation is a feature of CKD, but only recently has adipose tissue inflammation been 12 
proposed as a potential contributor to the development of cardiovascular complications in CKD.22,30 13 
We report here that lean CKD patients have more CD68-positive cells in their adipose tissue than 14 
healthy controls, suggesting that adipose inflammation may indeed be a feature of uremic fat. 15 
Although adipose tissue fibrosis is a hallmark of perturbed adipose function,31,32 we found no 16 
differences in the degree of adipose tissue fibrosis, assessed by collagen content, between lean CKD 17 
patients and controls. This could mean that either adipose tissue fibrosis is not a feature of kidney 18 
disease, or that we were not able to detect fibrosis, which might develop in another adipose tissue 19 
depot, or that fibrosis is not very apparent in non-obese individuals. Of interest was the significantly 20 
smaller adipocyte size in the lean kidney failure patients compared to controls. Considering the high 21 
CVD risk and insulin resistance associated with CKD, one could have expected an increased 22 
adipocyte size, which is coupled to blunted insulin signalling in both obese and non-obese 23 
individuals.33-35 On the other hand, the lean CKD subjects had lower BMI than the controls (although 24 
the difference in adipocyte size remained significant after correcting for BMI) and individuals with 25 
kidney failure suffer from protein wasting and cachexia,36 but this can be expected to affect primarily 26 
lean body mass rather than fat. However, perturbed adipose tissue fatty acid metabolism in CKD is 27 
indicated by the increased adipocyte lipolysis and reduced lipogenesis that is induced by an uremic 28 
milieu.19,37 Hence impaired adipose tissue uptake and storage of fatty acids in CKD, which could be 29 
reflected in alterations in adipocyte size, could lead to a pro-atherogenic blood lipid profile. 30 
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 1 
The proteomic analysis confirmed our hypothesis that CKD is associated with alterations in the 2 
functionality of adipose tissue. The multivariate analysis revealed that the protein composition of 3 
subcutaneous adipose tissue could distinguish between subjects with CKD and healthy controls. We 4 
identified several proteins whose expression differed significantly between CKD patients and controls. 5 
The two proteins that contributed most to the multivariate model including healthy controls and lean 6 
CKD patients were vimentin and AMBP, which were decreased and increased in CKD respectively. 7 
Although the lean CKD patients had lower BMI than the controls, we attribute alterations in vimentin 8 
and AMBP to the presence of CKD, as opposed to differences in obesity, since these alterations were 9 
maintained even after correction for BMI. Furthermore, we also quantified these proteins in a group of 10 
morbidly obese patients with CKD. The differences in both vimentin and AMBP between healthy 11 
controls and CKD patients were the same irrespective of whether the CKD patients were lean or 12 
obese, and their expression in adipose tissue did not correlate with BMI thereby indicating that CKD, 13 
rather than obesity, underlies alterations in vimentin and AMBP protein expression in uremic adipose 14 
tissue. 15 
 16 
Vimentin is a protein present in mesenchymal cells, including adipocytes, with different isoforms that 17 
are differentially regulated.38 Correspondingly, our proteomic analysis identified four protein spots in 18 
adipose tissue as vimentin (vimentin_1-4), with molecular weights in line with those reported 19 
previously (46-54KDa)39 and we confirmed this by Western blot. Of all the protein spots with lower 20 
expression in the lean CKD patients, vimentin_1 (the lowest molecular weight-vimentin spot) 21 
contributed most to the separation of the CKD and control subjects in the multivariate model. Western 22 
blot analysis confirmed that the lowest molecular weight isoforms of vimentin differed the most 23 
between controls and lean CKD. Vimentin is a lipid-droplet associated protein40,41 involved in the 24 
regulation of adipocyte lipolysis.39,42,43 Primary human adipocytes cultured with uremic serum show 25 
increased basal lipolysis and decreased perilipin expression,19 indicating that a uremic environment 26 
can alter lipid droplet metabolism, with vimentin having a known role in the latter. Moreover, higher 27 
vimentin expression is a hallmark of more insulin-sensitive adipose tissue.29 Thus vimentin plays an 28 
important role in adipose tissue function and dysregulation of these processes as a result of alterations 29 
in vimentin expression are likely to perturb adipose tissue, promoting cardiovascular events, such as 30 
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atherosclerosis,4 but it remains to be established whether and how different isoforms of vimentin affect 1 
human adipose tissue, and whether they are differentially regulated by the uremic milieu. 2 
 3 
Another adipose tissue protein that made a major contribution to the separation between the CKD 4 
patients and controls in the multivariate models and whose expression was much higher in the CKD 5 
patients was AMBP. Although produced mainly in the liver, AMBP protein is also expressed in adipose 6 
tissue (www.genecards.org). AMBP is a precursor protein that is cleaved into two functional proteins – 7 
alpha-1-microglobulin (A1M) and bikunin – with all the peptide sequences identified in the present 8 
mass spectrometry analysis within A1M. Since A1M binds and degrades free radicals and oxidising 9 
agents, and oxidative stress in adipose tissue is linked to obesity, inflammation, diabetes and other 10 
diseases,44,45 the high AMBP protein levels in adipose tissue of CKD patients indicate that the tissue is 11 
exposed to the damaging effects of free radicals, which can cause lipid and protein oxidation and cell 12 
death, and has a compromised functionality. 13 
 14 
We acknowledge some limitations of our study, in particular the small sample size and restriction to 15 
subcutaneous adipose tissue. It is possible that alterations in visceral and perivascular adipose tissue 16 
depots may have a greater impact on the development of CVD in CKD patients. Finally, the cross-17 
sectional nature of this study restricts our ability to draw causal conclusions. Yet, to the best of our 18 
knowledge, this is the first proteomic analysis of adipose tissue from CKD patients therefore we 19 
believe it provides relevant information. 20 
 21 
In conclusion, we have shown that adipose tissue of patients with CKD has an inflammatory 22 
phenotype, has smaller adipocytes and is exposed to oxidative stress, as manifested by high AMBP 23 
levels. Furthermore abnormal vimentin expression may affect lipid droplet metabolism and lipolysis 24 
rates. These data provide a novel perspective on how changes in adipose tissue could lead to 25 
increased risk of cardiovascular events in CKD.  26 
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Table 1. Characteristics of the study subjects. 
  Control CKD 
Number (M/F) 11 (3/8) 16 (9/7) 
Age (years) 45.6 ± 8.6 38.8 ± 14.8 
BMI (kg/m2) 26.2 ± 2.9 22.7 ± 2.1** 
GFR (mL/min) 133 ± 32 12 ± 7** 
CRP (mg/L) 1.0 ± 0.9 7.5 ± 17.9 
Glucose (mmol/L)a 5.2 ± 0.8 5.6 ± 1.0 
Na (mmol/L) 141 ± 1 139 ± 4 
K (mmol/L) 3.9 ± 0.2 4.8 ± 0.7** 
Creatinine (µmol/L) 63 ± 21 742 ± 284** 
Urea (mmol/L)b 4.6 ± 1.2 24.4 ± 9.4** 
Bilirubin (µmol/L)b 7 ± 2 8 ± 2 
ASAT (µkat/L) 0.37 ± 0.07 0.33 ± 0.11 
Leukocytes (x109/L) 6.3 ± 1.7 7.6 ± 2.4 
Hemoglobin (g/L) 139 ± 10 113 ± 20** 
Triglyceride (mmol/L)c N/A 1.7 ± 0.8 
Cholesterol (mmol/L) c N/A 4.8 ± 1.1 
HDL (mmol/L) c N/A 1.5 ± 0.6 
Values are given as mean ± SD. a data available from 14 CKD subjects; b data available from 12 CKD 
subjects, c data available from 15 CKD subjects. BMI – body mass index, GFR – glomerular filtration 
rate [for males GFR = (1.23 x [140 - age] x weight)/serum creatinine; for females GFR = (1.04 x [140 - 
age] x weight)/serum creatinine], CRP – C-reactive protein (measured with a high sensitivity method), 
ASAT – aspartate aminotransferase, HDL – high-density lipoprotein cholesterol, N/A – data not 
available. *p≤0.05, **p≤0.01 for differences between groups (Student’s t-test). 
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Table 2. Adipose tissue protein spots significant in the OPLS-DA analysis and identified by LC-MS/MS.   
Protein name 
Protein 
abbreviation 
Normalized 
spot volume 
Controls 
Normalized 
spot volume 
CKD 
Loading 
value in 
OPLS-DA 
Proteins with higher expression in CKD 
    
Alpha-1-microglobulin/bikunin precursor AMBP 0.53±0.13 2.14±0.52** 0.1734 
Glycerol-3-phosphate dehydrogenase [NAD(+)], cytoplasmic GPDA 1.02±0.29 1.67±0.41** 0.1438 
Glyceraldehyde 3-phosphate dehydrogenase GAPDH 1.10±0.42 1.88±0.59** 0.1438 
Annexin A6 ANXA6 1.09±0.34 2.28±0.70** 0.1399 
Transthyretin TTHY 1.17±0.43 2.73±0.95** 0.1323 
Alpha-1-antitrypsin_1 A1AT 1.20±0.45 1.78±0.51* 0.1306 
Alpha-1-antitrypsin_2 A1AT 1.16±0.44 1.66±0.46* 0.1259 
14-3-3 protein zeta/delta 1433Z 1.21±0.32 1.74±0.56* 0.1036 
Vimentin_3 VIME 1.49±0.72 2.08±0.82 0.1024 
Vimentin_4 VIME 1.42±0.62 1.91±0.79 0.0971 
Annexin A5_2 ANXA5 1.11±0.54 1.67±0.75 0.0947 
Alpha-1-antitrypsin_3 A1AT 1.42±0.49 1.53±0.50 0.0907 
14-3-3 protein epsilon 1433E 1.20±0.35 1.48±0.42 0.0858 
Serum albumin_2 ALBU 1.13±0.23 1.25±0.18 0.0839 
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Proteins with lower expression in CKD 
 
 
Vimentin_1 VIME 1.58±0.26 0.94±0.28** -0.1675 
Vimentin_2 VIME 1.29±0.56 0.68±0.35** -0.1372 
Serum albumin_1 ALBU 2.52±1.05 1.31±0.54** -0.1140 
Annexin A5_1 ANXA5 2.15±1.38 0.95±0.77* -0.1003 
In cases where two or more spots were identified as the same protein, spots are distinguished by successive numbering (eg vimentin_1, vimentin_2 etc). 
*p≤0.05, **p≤0.01 for differences between groups (Student’s t-test). 
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Figure legends 1 
Figure 1. Representative staining for CD68 in subcutaneous adipose tissue sections from (A) a 2 
healthy control and (B) a lean CKD patient. Positive (brown) staining indicated with arrows. Scale bar 3 
20µm, magnification 40x. (C) Infiltration of CD68-positive inflammatory cells (number of positive cells 4 
per 10mm2 tissue area) in adipose tissue of control subjects (n=9, black fill) and patients with CKD 5 
(n=14, blue fill). *p<0.05 for differences between the groups. (D) Comparison of collagen content in 6 
adipose tissue of controls (n=10, black fill) and CKD patients (n=14, blue fill). (E) Adipocyte size 7 
comparison between controls (n=9, black fill) and patients with kidney failure (n=13, blue fill). The 8 
average number of cells counted was 71 ± 34 per individual. **p<0.01 for differences between the 9 
groups (Mann-Whitney U-test). Box plots represent median (within-box line), minimum and maximum 10 
values (whiskers). 11 
Figure 2. Representative 2 dimensional gels (Cy5 labelled) of an adipose tissue protein extract from a 12 
control individual (A) and a lean patient with CKD (B). The isoelectric point range is 3-10, non-linear. 13 
Spots that were statistically significant in the OPLS-DA model and that were picked for identification 14 
are marked in yellow. Spots that were not significant in the model and were identified are marked in 15 
pink. 1433E – 14-3-3 protein epsilon, 1433G - 14-3-3 protein gamma, 1433Z – 14-3-3 protein 16 
zeta/delta, A1AT – alpha-1-antitrypsin, ACTB – actin, cytoplasmic 1, ALBU – serum albumin, 17 
ALDH1A1 – retinal dehydrogenase 1, AMBP – alpha-1-microglobulin/bikunin precursor, APOAIV – 18 
apolipoprotein AIV, ANXA5 – annexin A5, ANXA6 – annexin A6, CA1 – carbonic anhydrase 1, FABP4 19 
– fatty acid binding protein 4, GAPDH – glyceraldehyde-3-phosphate dehydrogenase, GPDH – 20 
glycerol-3-phosphate dehydrogenase, GSTP1 – glutathione S-transferase P, HBA1 – hemoglobin 21 
subunit alpha, HBB – hemoglobin subunit beta, IGHG1 – Ig gamma-1 chain C, PRDX2 – peroxiredoxin 22 
2, TTHY – transthyretin, VIME – vimentin.  23 
Figure 3. OPLS-DA analysis of protein spot volumes of adipose tissue from controls and lean patients 24 
with CKD. The presence or absence of CKD was used as the Y vector. The analysis was performed 25 
on 7 control individuals, 13 CKD patients and 202 protein spots. The Hotelling’s T2 (based on 95% 26 
confidence level) tolerance ellipse is shown in the score plot (A), which shows all the individuals 27 
analyzed (controls yellow, CKD patients blue). Predictive loadings representing the analyzed protein 28 
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spots are presented as a scatter plot for all protein spots (B) and as a column plot for spots that were 1 
identified and were significant in the model (C). In (B) and (C) vimentin_1 and AMBP are marked in 2 
red. For protein name abbreviations, see legend to Figure 2. The significance of the differentially 3 
expressed spots was calculated as the difference between the absolute value of the loadings 4 
(ABS[loading]) and the absolute value of the corresponding jack-knife confidence interval (ABS[CI]). A 5 
positive difference indicates significance.  6 
Figure 4. Western blot for vimentin and AMBP in adipose tissue from controls (n=7) and lean CKD 7 
patients (n=13). Beta actin was used as loading control. Half the CKD samples and all the control 8 
samples were run on one gel and the other half of the CKD samples and the same control samples 9 
were run on a second gel (space restrictions prevented the loading of all samples on one gel). Blots of 10 
the control samples are shown only once for ease of understanding. AMBP is consistently higher in 11 
the CKD patients, while the lower molecular weight forms of vimentin are generally lower in the CKD 12 
patients as compared to controls (visual assessment). 13 
Figure 5. Comparison of (A) vimentin_1 and (B) AMBP spot volumes between controls (n=7, black 14 
fill), lean CKD patients (n=13, light blue fill) and obese CKD patients (n=9, dark blue fill). *p≤0.05, 15 
**p≤0.01 for differences between the groups (ANOVA followed by Fisher’s LSD post-hoc tests). Box 16 
plots represent median (within-box line), minimum and maximum values (whiskers). 17 
Supplemental Figure 1. Representative images of picrosirius red collagen staining of subcutaneous 18 
adipose tissue sections from a control individual (A) and a lean CKD patient (B). Positive staining (red) 19 
is visible between adipocytes as reticular fibers as well as clusters of thicker collagen bundles. Scale 20 
bar = 20µm. 21 
Supplemental Figure 2. Representative images of transformed ImageJ pictures of subcutaneous 22 
adipose tissue sections from a control individual (A) and a lean CKD patient (B) used for calculation of 23 
adipocyte size. 24 
Supplemental Figure 3. OPLS-DA analysis of protein spot volumes of adipose tissue from healthy 25 
controls and obese patients with CKD. The presence or absence of CKD was used as the Y vector. 26 
The analysis was performed on 7 control individuals, 9 obese CKD patients and 202 protein spots. 27 
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The Hotelling’s T2 (based on 95% confidence level) tolerance ellipse is shown in the score plot (A), 1 
which shows all the individuals analyzed (controls yellow, CKD patients blue). Predictive loadings 2 
representing the analyzed protein spots are presented as a scatter plot for all protein spots (B). 3 
Vimentin_1 and AMBP are marked in red. 4 
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Figure 5
